A perspective on the development of plant-made vaccines in the fight against ebola virus

Frontiers in Immunology

Volumn 8, Issue MAR, 2017, Pages

  Rosales Mendoza, Sergio ^a   Nieto Gómez, Ricardo ^a   Angulo, Carlos ^b  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS DEL NOROESTE   (Mexico)

Author keywords

Ebola virus; Global vaccination; Glycoprotein antigen; Low cost vaccine; Molecular pharming; Mucosal immunization; VP antigen

Indexed keywords

ANTIGEN; CHOLERA TOXIN; VIRAL PROTEIN;

EASTERN EQUINE ENCEPHALITIS VIRUS; EBOLAVIRUS; EBOV GP GENE; GENE; HUMAN PARAINFLUENZA VIRUS 3; IMMUNOGENICITY; NONHUMAN; PLAQUE FORMING CELL; PROTEIN EXPRESSION; REVIEW; VIRUS REPLICATION;

EID: 85017225316     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00252     Document Type: Review

References (109)

1. Kosal ME. A new role for public health in bioterrorism deterrence. Front Public Health (2014) 2:278. doi:10.3389/fpubh.2014.00278
2. Jun SR, Leuze MR, Nookaew I, Uberbacher EC, Land M, Zhang Q, et al. Ebolavirus comparative genomics. FEMS Microbiol Rev (2015) 39:764-78. doi:10.1093/femsre/fuv031
3. Marsh GA, Haining J, Robinson R, Foord A, Yamada M, Barr JA. Ebola Reston virus infection of pigs: clinical significance and transmission potential. J Infect Dis (2011) 204:S804-9. doi:10.1093/infdis/jir300
4. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol (2010) 155:2083-103. doi:10.1007/s00705-010-0814-x
5. Lado M, Walker NF, Baker P, Haroon S, Brown CS, Youkee D, et al. Clinical features of patients isolated for suspected Ebola virus disease at Connaught Hospital, Freetown, Sierra Leone: a retrospective cohort study. Lancet Infect Dis (2015) 15:1024-33. doi:10.1016/S1473-3099(15)00137-1
6. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med (2016) 374:1647-60. doi:10.1056/NEJMoa1502924
7. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature (2014) 514:47-53. doi:10.1038/nature13777
8. Tully CM, Lambe T, Gilbert SC, Hill AS. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. Lancet Infect Dis (2015) 15:356-9. doi:10.1016/S1473-3099(14)71071-0
9. Avesani L, Bortesi L, Santi L, Falorni A, Pezzotti M. Plant-made pharmaceuticals for the prevention and treatment of autoimmune diseases: where are we? Expert Rev Vaccines (2010) 9:957-69. doi:10.1586/erv.10.82
10. Avesani L, Merlin M, Gecchele E, Capaldi S, Brozzetti A, Falorni A, et al. Comparative analysis of different biofactories for the production of a major diabetes autoantigen. Transgenic Res (2014) 23:281-91. doi:10.1007/s11248-013-9749-9
11. Alvarez ML, Pinyerd HL, Crisantes JD, Rigano MM, Pinkhasov J, Walmsley AM, et al. Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice. Vaccine (2006) 24:2477-9. doi:10.1016/j.vaccine.2005.12.057
12. Su J, Zhu L, Sherman A, Wang X, Lin S, Kamesh A, et al. Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia. Biomaterials (2015) 70:84-93. doi:10.1016/j.biomaterials.2015.08.004
13. Davoodi-Semiromi A, Schreiber M, Nalapalli S, Verma D, Singh ND, Banks RK, et al. Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery. Plant Biotechnol J (2010) 8:223-42. doi:10.1111/j.1467-7652.2009.00479.x
14. Monreal-Escalante E, Govea-Alonso DO, Hernández M, Cervantes J, Salazar-González JA, Romero-Maldonado A, et al. Towards the development of an oral vaccine against porcine cysticercosis: expression of the protective HP6/TSOL18 antigen in transgenic carrots cells. Planta (2016) 243:675-85. doi:10.1007/s00425-015-2431-0
15. Hernández M, Rosas G, Cervantes J, Fragoso G, Rosales-Mendoza S, Sciutto E. Transgenic plants: a 5-year update on oral antipathogen vaccine development. Expert Rev Vaccines (2014) 13:1523-36. doi:10.1586/14760584.2014.953064
16. Chan HT, Daniell H. Plant-made oral vaccines against human infectious diseases-are we there yet? Plant Biotechnol (2015) 13:1056-70. doi:10.1111/pbi.12471
17. Streatfield SJ, Kushnir N, Yusibov V. Plant-produced candidate countermeasures against emerging and reemerging infections and bioterror agents. Plant Biotechnol J (2015) 13:1136-59. doi:10.1111/pbi.12475
18. Ward BJ, Landry N, Trépanier S, Mercier G, Dargis M, Couture M. Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. Vaccine (2014) 32:6098-106. doi:10.1016/j.vaccine
19. Chichester JA, Jones RM, Green BJ, Stow M, Miao F, Moonsammy G, et al. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults. Viruses (2012) 4:3227-44. doi:10.3390/v4113227
20. Cummings JF, Guerrero ML, Moon JE, Waterman P, Nielsen RK, Jefferson S, et al. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a phase 1 dose-escalation study in healthy adults. Vaccine (2014) 32:2251-9. doi:10.1016/j.vaccine.2013.10.017
21. Bosch D, Schots A. Plant glycans: friend or foe in vaccine development? Expert Rev Vaccines (2010) 9:835-42. doi:10.1586/erv.10.83
22. Landry N, Pillet S, Favre D, Poulin JF, Trépanier S, Yassine-Diab B, et al. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin Immunol (2014) 154(2):164-77. doi:10.1016/j.clim.2014.08.003
23. Pavot V. Ebola virus vaccines: where do we stand? Clin Immunol (2016) 173:44-9. doi:10.1016/j.clim.2016.10.016
24. Mire CE, Geisbert TW, Feldmann H, Marzi A. Ebola virus vaccines-reality or fiction? Expert Rev Vaccines (2016) 15:1421-30. doi:10.1080/14760584.2016.1178068
25. Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL. Epitopes involved in antibody-mediated protection from Ebola virus. Science (2000) 287:1664-6. doi:10.1126/science.287.5458.1664
26. Wong G, Richardson JS, Pillet S, Patel A, Qiu X, Alimonti J, et al. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci Transl Med (2012) 4:158ra146. doi:10.1126/scitranslmed
27. Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A (2013) 110:1893-8. doi:10.1073/pnas.1209591110
28. Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med (2011) 17:1128-31. doi:10.1038/nm.2447
29. Food and Drug Administration. (2014). Available from: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm
30. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, Jaax NK, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis (1999) 179(Suppl 1):S203-17. doi:10.1086/514305
31. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis (1998) 178:651-61. doi:10.1086/515386
32. Ebihara H, Zivcec M, Gardner D, Falzarano D, LaCasse R, Rosenke R, et al. A Syrian golden hamster model recapitulating Ebola hemorrhagic fever. J Infect Dis (2013) 207:306-18. doi:10.1093/infdis/jis626
33. Carrion R Jr, Ro Y, Hoosien K, Ticer A, Brasky K, de la Garza M, et al. A small nonhuman primate model for filovirus-induced disease. Virology (2011) 420:117-24. doi:10.1016/j.virol.2011.08.022
34. Cross RW, Mire CE, Borisevich V, Geisbert JB, Fenton KA, Geisbert TW. The domestic ferret (Mustela putorius furo) as a lethal infection model for 3 species of ebolavirus. J Infect Dis (2016) 214:565-9. doi:10.1093/infdis/jiw209
35. Kozak R, He S, Kroeker A, de La Vega MA, Audet J, Wong G, et al. Ferrets infected with Bundibugyo virus or Ebola virus recapitulate important aspects of human filovirus disease. J Virol (2016) 90:9209-23. doi:10.1128/JVI.01033-16
36. Ye L, Yang C. Development of vaccines for prevention of Ebola virus infection. Microbes Infect (2015) 17:98-108. doi:10.1016/j.micinf.2014.12.004
37. Hoenen T, Groseth A, Feldmann H. Current Ebola vaccines. Expert Opin Biol Ther (2012) 12:859-72. doi:10.1517/14712598.2012.685152
38. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 11:786-90. doi:10.1038/nm1258
39. Sullivan N, Geisbert T, Geisbert J, Shedlock D, Xu L, Lamoreaux L, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 3:e177. doi:10.1371/journal.pmed.0030177
40. Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol (2007) 81:6379-88. doi:10.1128/JVI.00105-07
41. Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, Feldmann F, et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog (2013) 9:e1003389. doi:10.1371/journal.ppat.1003389
42. Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, et al. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with Ebolavirus. J Virol (2013) 87:4952-64. doi:10.1128/JVI.03361-12
43. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis (2007) 196(Suppl 2):S430-7. doi:10.1086/520583
44. Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol (2008) 15:460-7. doi:10.1128/CVI.00431-07
45. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 408:605-9. doi:10.1038/35046108
46. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine (2010) 29:304-13. doi:10.1016/j.vaccine.2010.10.037
47. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against Ebola virus challenge. Nat Med (2014) 20:1126-9. doi:10.1038/nm.3702
48. Halfmann P, Ebihara H, Marzi A, Hatta Y, Watanabe S, Suresh M, et al. Replication-deficient Ebolavirus as a vaccine candidate. J Virol (2009) 83:3810-5. doi:10.1128/JVI.00074-09
49. Marzi A, Halfmann P, Hill-Batorski L, Feldmann F, Shupert WL, Neumann G, et al. Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates. Science (2015) 348:439-42. doi:10.1126/science.aaa4919
50. Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, et al. Safety and immunogenicity of novel adenovirus type 26-and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA (2016) 315:1610-23. doi:10.1001/jama.2016.4218
51. Marzi A, Robertson SJ, Haddock E, Feldmann F, Hanley PW, Scott DP, et al. Ebola vaccine. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science (2015) 349:739-42. doi:10.1126/science.aab3920
52. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 26:6894-900. doi:10.1016/j.vaccine.2008.09.082
53. Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS One (2009) 4:e5547. doi:10.1371/journal.pone.0005547
54. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 82:5664-8. doi:10.1128/JVI.00456-08
55. Lai L, Davey R, Beck A, Xu Y, Suffredini AF, Palmore T, et al. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA (2015) 313:1249-55. doi:10.1001/jama.2015
56. Günther S, Feldmann H, Geisbert TW, Hensley LE, Rollin PE, Nichol ST, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis (2011) 204(Suppl 3):S785-90. doi:10.1093/infdis/jir298
57. Mire CE, Matassov D, Geisbert JB, Latham TE, Agans KN, Xu R, et al. Single dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature (2015) 520:688-91. doi:10.1038/nature14428
58. DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine (2010) 29:17-25. doi:10.1016/j.vaccine.2010.10.024
59. Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis (2015) 15:1156-66. doi:10.1016/S1473-3099(15)00154-1
60. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the guinea ring vaccination cluster-randomised trial. Lancet (2015) 386:857-66. doi:10.1016/S0140-6736(15)61117-5
61. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola ça Suffit!). Lancet (2017) 389:505-18. doi:10.1016/S0140-6736(16)32621-6
62. Konduru K, Bradfute SB, Jacques J, Manangeeswaran M, Nakamura S, Morshed S, et al. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Vaccine (2011) 29:2968-77. doi:10.1016/j.vaccine.2011.01.113
63. Phoolcharoen W, Dye JM, Kilbourne J, Piensook K, Pratt WD, Arntzen CJ, et al. A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. Proc Natl Acad Sci U S A (2011) 108:20695-700. doi:10.1073/pnas.1117715108
64. Martins KA, Jahrling PB, Bavari S, Kuhn JH. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines (2016) 15:1101-12. doi:10.1080/14760584.2016.1187566
65. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol (2006) 13:1267-77. doi:10.1128/CVI.00162-06
66. Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z, Hendel CS, et al. Safety and immunogenicity of DNA vaccines encoding Ebola virus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis (2015) 211:549-57. doi:10.1093/infdis/jiu511
67. Cooper CL, Bavari S. A race for an Ebola vaccine: promises and obstacles. Trends Microbiol (2015) 23:65-6. doi:10.1016/j.tim.2014.12.005
68. Mire CE, Geisbert JB, Agans KN, Satterfield BA, Versteeg KM, Fritz EA, et al. Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS One (2014) 9:e94355. doi:10.1371/journal.pone.0094355
69. Wong G, Audet J, Fernando L, Fausther-Bovendo H, Alimonti JB, Kobinger GP, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine (2014) 32:5722-9. doi:10.1016/j.vaccine.2014.08.028
70. Kennedy SB, Neaton JD, Lane HC, Kieh MWS, Massaquoi MBF, Touchette NA, et al. Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: design, procedures, and challenges. Clin Trials (2016) 13:49-56. doi:10.1177/1740774515621037
71. Becquart P, Mahlakõiv T, Nkoghe D, Leroy EM. Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus. PLoS One (2014) 9:e96360. doi:10.1371/journal.pone.0096360
72. Vaughan K, Ponomarenko J, Sette A. (2014). Ebola Virus Related Immune Epitope Data Curated in the IEDB. Available from: http://help.iedb.org/entries/51011785-Ebola-virus-related-immune-epitope-data-curated-in-the-IEDB
73. Takada A, Ebihara H, Feldmann H, Geisbert TW, Kawaoka Y. Epitopes required for antibody-dependent enhancement of Ebola virus infection. J Infect Dis (2007) 196(Suppl 2):S347-56. doi:10.1086/520581
74. Lee JE, Saphire EO. Ebola virus glycoprotein structure and mechanism of entry. Future Virol (2009) 4:621-35. doi:10.2217/fvl.09.56
75. Wang Y, Liu Z, Dai Q. A highly immunogenic fragment derived from Zaire Ebola virus glycoprotein elicits effective neutralizing antibody. Virus Res (2014) 189:254-61. doi:10.1016/j.virusres.2014.06.001
76. Khan MA, Hossain MU, Rakib-Uz-Zaman SM, Morshed MN. Epitope-based peptide vaccine design and target site depiction against Ebola viruses: an immunoinformatics study. Scand J Immunol (2015) 82:25-34. doi:10.1111/sji.12302
77. Spangler BD. Structure of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev (1992) 56:622-47.
78. Guan C, Ji J, Jin C, Wang G, Li X, Guan W. Expression of cholera toxin B subunit-lumbrokinase in edible sunflower seeds-the use of transmucosal carrier to enhance its fusion protein's effect on protection of rats and mice against thrombosis. Biotechnol Prog (2014) 30:1029-39. doi:10.1002/btpr.1963
79. Rosales-Mendoza S, Soria-Guerra RE, Moreno-Fierros L, Govea-Alonso DO, Herrera-Díaz A, Korban SS, et al. Immunogenicity of nuclear-encoded LTB:ST fusion protein from Escherichia coli expressed in tobacco plants. Plant Cell Rep (2011) 30:1145-52. doi:10.1007/s00299-011-1023-0
80. Yu J, Langridge WH. A plant-based multicomponent vaccine protects mice from enteric diseases. Nat Biotechnol (2001) 19:548-52. doi:10.1038/89297
81. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell (1988) 55:1189-93. doi:10.1016/0092-8674(88)90263-2
82. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem (1994) 269:10444-50.
83. Scotti N, Rybicki EP. Virus-like particles produced in plants as potential vaccines. Expert Rev Vaccines (2013) 12:211-24. doi:10.1586/erv.12.147
84. Marusic C, Rizza P, Lattanzi L, Mancini C, Spada M, Belardelli F, et al. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J Virol (2001) 75:8434-9. doi:10.1128/JVI.75.18.8434-8439.2001
85. Chargelegue D, Drake P, Obregon P, Prada A, Fairweather N, Ma JK. Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plants. Infect Immun (2005) 73:5915-22. doi:10.1128/IAI.73.9.5915-5922.2005
86. Komarova TV, Baschieri S, Donini M, Marusic C, Benvenuto E, Dorokhov YL. Transient expression systems for plant-derived biopharmaceuticals. Expert Rev Vaccines (2010) 9:859-76. doi:10.1586/erv.10.85
87. Thuenemann EC, Meyers AE, Verwey J, Rybicki EP, Lomonossoff GP. A method for rapid production of heteromultimeric protein complexes in plants: assembly of protective bluetongue virus-like particles. Plant Biotechnol J (2013) 11(7):839-46. doi:10.1111/pbi.12076
88. D'aoust M, Couture M, Lavoie P, Vezina L. Virus Like Particle Production in Plants. U.S. Patent No 20,130,344,100 (2013).
89. Phoolcharoen W, Bhoo SH, Lai H, Ma J, Arntzen CJ, Chen Q, et al. Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana. Plant Biotechnol J (2011) 9:807-16. doi:10.1111/j.1467-7652.2011.00593.x
90. Salazar-González JA, Monreal-Escalante E, Herrera Díaz A, Koop HU, Rosales-Mendoza S. Plastid-based expression strategies. In: Mendoza SR, editor. Genetically Engineered Plants as a Source of Vaccines Against Wide Spread Diseases-An Integrated View. New York, NY: Springer (2014). p. 61-78.
91. Lelivelt CL, van Dun KM, de Snoo CB, McCabe MS, Hogg BV, Nugent JM. Plastid transformation in lettuce (Lactuca sativa L.) by polyethylene glycol treatment of protoplasts. Methods Mol Biol (2014) 1132:317-30. doi:10.1007/978-1-62703-995-620
92. Ruhlman T, Ahangari R, Devine A, Samsam M, Daniell H. Expression of cholera toxin B-proinsulin fusion protein in lettuce and tobacco chloroplasts-oral administration protects against development of insulitis in non-obese diabetic mice. Plant Biotechnol J (2007) 5:495-510. doi:10.1111/j.1467-7652.2007.00259.x
93. Lakshmi PS, Verma D, Yang X, Lloyd B, Daniell H. Low cost tuberculosis vaccine antigens in capsules: expression in chloroplasts, bio-encapsulation, stability and functional evaluation in vitro. PLoS One (2013) 8:e54708. doi:10.1371/journal.pone.0054708
94. Alvarez ML, Topal E, Martin F, Cardineau GA. Higher accumulation of F1-V fusion recombinant protein in plants after induction of protein body formation. Plant Mol Biol (2010) 72:75-89. doi:10.1007/s11103-009-9552-4
95. Curtis IS. Lettuce (Lactuca sativa L.). Methods Mol Biol (2006) 343:449-58. doi:10.1385/1-59745-130-4:449
96. Rosales-Mendoza S, Soria-Guerra RE, de Jesús Olivera-Flores MT, López-Revilla R, Argüello-Astorga GR, Jimémez-Bremont JF, et al. Expression of Escherichia coli heat-labile enterotoxin b subunit (LTB) in carrot (Daucus carota L.). Plant Cell Rep (2007) 26:969-76. doi:10.1007/s00299-007-0310-2
97. Balestrazzi A, Carbonera D, Cella R. Transformation of Daucus carota hypocotyls mediated by Agrobacterium tumefaciens. J Genet Breed (1991) 45:135-40.
98. Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, et al. A phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells Mol Dis (2014) 53:253-60. doi:10.1016/j.bcmd.2014.05.004
99. Shaaltiel Y, Gingis-Velitski S, Tzaban S, Fiks N, Tekoah Y, Aviezer D. Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease. Plant Biotechnol J (2015) 13:1033-40. doi:10.1111/pbi.12366
100. Smith ML, Richter L, Arntzen CJ, Shuler ML, Mason HS. Structural characterization of plant-derived hepatitis B surface antigen employed in oral immunization studies. Vaccine (2003) 21:4011-21. doi:10.1016/S0264-410X(03)00268-8
101. Meador LR, Mor TS. Meeting report VLPNPV: session 5: plant based technology. Hum Vaccin Immunother (2014) 10:3068-73. doi:10.4161/21645515.2014.979693
102. Huang Z, Elkin G, Maloney BJ, Beuhner N, Arntzen CJ, Thanavala Y, et al. Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses. Vaccine (2005) 23:1851-8. doi:10.3748/wjg.v9.i5.996
103. Lerouge P, Bardor M, Pagny S, Gomord V, Faye L. N-glycosylation of recombinant pharmaceutical glycoproteins produced in transgenic plants: towards an humanisation of plant N-glycans. Curr Pharm Biotechnol (2000) 1:347-54. doi:10.2174/1389201003378843
104. Hamorsky KT, Kouokam JC, Jurkiewicz JM, Nelson B, Moore LJ, Husk AS, et al. N-glycosylation of cholera toxin B subunit in Nicotiana benthamiana: impacts on host stress response, production yield and vaccine potential. Sci Rep (2015) 5:8003. doi:10.1038/srep08003
105. Kim HS, Jeon JH, Lee KJ, Ko K. N-glycosylation modification of plant-derived virus-like particles: an application in vaccines. Biomed Res Int (2014) 2014:249519. doi:10.1155/2014/249519
106. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med (1998) 4(5):607-9. doi:10.1038/nm0598-607
107. Chikwamba RK, Scott MP, Mejía LB, Mason HS, Wang K. Localization of a bacterial protein in starch granules of transgenic maize kernels. Proc Natl Acad Sci U S A (2003) 100:11127-32. doi:10.1073/pnas.1836901100
108. Pepponi I, Diogo GR, Stylianou E, van Dolleweerd CJ, Drake PM, Paul MJ, et al. Plant-derived recombinant immune complexes as self-adjuvanting TB immunogens for mucosal boosting of BCG. Plant Biotechnol J (2014) 12:840-50. doi:10.1111/pbi.12185
109. Pniewski T, Kapusta J, Bociag P, Wojciechowicz J, Kostrzak A, Gdula M, et al. Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation. J Appl Genet (2011) 52:125-36. doi:10.1007/s13353-010-0001-5